SLC2A3 is an important member of the glucose transporter superfamily. It has been recently suggested that upregulation of SLC2A3 is associated with poor survival and acts as a prognostic marker in a variety of tumors. Unfortunately, the prognostic role of SLC2A3 in head and neck squamous cell carcinoma (HNSC) is less known. In the present study, we analyzed SLC2A3 expression in HNSC and its correlation with prognosis using TCGA and GEO databases. The results showed that SLC2A3 mRNA expression was higher in HNSC compared with adjacent normal tissues, which was validated with our 9 pairs of HNSC specimens. Moreover, high SLC2A3 expression predicted poor prognosis in HNSC patients. Mechanistically, GSEA revealed that high expression of SLC2A3 was enriched in epithelial-mesenchymal transition (EMT) and NF-κB signaling. In HNSC cell lines, SLC2A3 knockdown inhibited cell proliferation and migration. In addition, NF-κB P65 and EMT-related gene expression was suppressed upon SLC2A3 knockdown, indicating that SLC2A3 may play a preeminent role in the progression of HNSC through the NF-κB/EMT axis. Meanwhile, the expression of SLC2A3 was negatively correlated with immune cells, suggesting that SLC2A3 may be involved in the immune response in HNSC. The correlation between SLC2A3 expression and drug sensitivity was further assessed. In conclusion, our study demonstrated that SLC2A3 could predict the prognosis of HNSC patients and mediate the progression of HNSC via the NF-κB/EMT axis and immune responses.
31 December 2022 in European Archives of Oto-Rhino-Laryngology
Direct comparison of the long-term effectiveness and safety of biologics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is lacking. The study aimed to compare the long-term efficacy and safety of various biologics in the management of CRSwNP. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from database inception to March 2024, to identify all relevant literature on the use of biologics for CRSwNP. The research protocol was registered on PROSPERO.Two independent reviewers screened the studies, extracted the data, and performed a quality assessment using the Cochrane Risk of Bias tool. Network meta-analysis was conducted using STATA 17.0 and Review Manager (Version 5.3). Six studies with a minimum follow-up period of 52-weeks were analyzed, demonstrating the superior long-term efficacy of dupilumab compared to the other three biologics. The surface under the cumulative ranking curve were 100% for Nasal Polyp Score (NPS), 72.7% for Sino-Nasal Outcome Test-22 (SNOT-22), 94.6% for Visual Analogue Scale (VAS), and 100% for Nasal Congestion Score (NCS). In the comparison of NPS, dupilumab showed improvements of 1.84 (95% Confidence Interval [95% CI 0.78, 2.91]) over mepolizumab and 2.31 (95% CI 0.99, 3.63) over benralizumab. Among the symptom scores evaluated, only dupilumab achieved a significant improvement in NCS compared to benralizumab, with an improvement of 0.74 (95% CI 0.86, 1.19). No significant differences in adverse events was observed between biologics treatment or versus placebo. Treatment with dupilumab in patients with CRSwNP has shown superior long-term efficacy in reducing NPS and various symptom scores compared to other biologics. However, the results should be interpreted with caution due to the heterogeneity of patient characteristics across the included studies (e.g., disease severity, history of surgery, use of oral corticosteroids).
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) pathogenesis might be impacted by autophagy. Nevertheless, autophagy-related gene utilization as a disease indicator about the course of CRSwNP has yet to be elucidated. Objective: This investigation aimed at discovering pivotal molecules related to autophagy to identify potential treatment targets for CRSwNP. Methods: The dataset GSE136825 was obtained via the Gene Expression Omnibus (GEO) database, and afterward, differentially expressed genes (DEGs) analysis linked to autophagy was employed via the R software. A comprehensive examination of autophagy-related DEGs was conducted using functional analytic techniques. The utilization of the protein-protein interaction (PPI) network facilitated hub gene identification. Quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry staining techniques were performed to validate the expression levels of the central genes in clinical samples. Correlation analysis was performed to examine the correlation between hub genes and disease severity parameters. Results: A comprehensive set of 86 autophagy-related DEGs were discovered. The functional enrichment analysis of autophagy-related DEGs revealed the identification of enrichment terms involved with the autophagy process. The results obtained from the PPI analysis suggest that there was interaction among the autophagy-related genes. The qRT-PCR, immunohistochemistry staining, and western blot techniques yielded results, demonstrated that CXCR4, HMOX1, and SPP1 expression levels in CRSwNP agreed with the bioinformatics analysis of the dataset. Furthermore, a favorable association between CXCR4, HMOX1, and SPP1 expression levels with illness severity indicators was found. Conclusion: Bioinformatics analysis yielded 86 autophagy-related DEGs in CRSwNP. CXCR4, HMOX1, and SPP1 regulation of autophagy has been confirmed in CRSwNP progression and pathogenesis.